US Clinics Marketing Unproven and Unlicensed Adipose-Derived Autologous Stem Cell Interventions
May 2015
in “
Regenerative Medicine
”
Studysummary This commentary explores the marketing of unproven and unlicensed adipose-derived stem cell treatments in US clinics, highlighting concerns about patient safety and regulatory challenges.
Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
In 2015, the document expressed concern over the rapid growth of US clinics offering unproven and unlicensed stem cell treatments derived from adipose tissue for various conditions, including hair restoration. The Cell Surgical Network, with 48 clinics, was specifically mentioned for promoting these treatments without evidence from randomized controlled trials. The document criticized the use of FDA-unapproved medical devices to produce stem cell products, the questionable informed consent process, and the lack of proper FDA clearance. It reported that the FDA had started to issue warning letters to some clinics and highlighted the position of professional societies like ASAPS and ASPS against the marketing of unproven stem cell procedures. The document called for increased FDA oversight, public awareness, critical journalism, and caution for investors, emphasizing the need to protect patients and investors from the risks associated with these clinics.
